Firmonertinib vs placebo for early-stage lung cancer with rare EGFR mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old (or 20 in Japan/Taiwan).
- You have a type of lung cancer called non-small cell lung cancer that is not mostly squamous cells.
- You have had full surgical removal of your lung tumor (no cancer left behind) and lymph node dissection.
- Your cancer stage after surgery is IB, II, IIIA, or IIIB (only T3N2M0 for IIIB).
- Your tumor has an uncommon EGFR mutation (exon 20 insertion, PACC, or classical-like) found by a special test.
- You have not had any prior cancer treatment except standard platinum-based chemotherapy after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill (firmonertinib) given before and after surgery for stage II–III lung adenocarcinoma that has an EGFR mutation. The goal is to see if this approach can shrink the tumor before surgery and reduce the chance of cancer coming back.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This trial tests a combination of two targeted drugs (firmonertinib and bevacizumab) given before surgery for people with early-stage, EGFR-mutated lung cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
This trial tests a new targeted pill (Firmonertinib) combined with standard chemotherapy for stage III lung cancer that cannot be removed by surgery. It is for people with a specific EGFR mutation, and the goal is to see if the combo helps shrink or control the cancer.
Hear when a new Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.